Q-omics provides the consensus-scored RANBP3 profile across patient tissues and cancer cell-line models. RANBP3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RANBP3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RANBP3 protein abundance shows 23,627 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where RANBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RANBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RANBP3 survival associations across molecular data types. RANBP3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RANBP3 RNA expression–survival associations across cancer types. High RANBP3 expression shows unfavorable associations in ACC, KICH, LIHC and UCS, but favorable associations in HNSC and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RANBP3 RNA expression.
This table summarizes RANBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RANBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RANBP3 shows lower tumor expression in LUAD and higher tumor expression in COAD, HNSC, LIHC, CHOL and BRCA. The COAD box plot shows higher RANBP3 RNA expression in tumor versus normal tissue (log2 FC = +0.798, t-test p < 0.001).
This table shows molecular features associated with RANBP3 in patient tissues and cancer cell lines. In patient samples, RANBP3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RANBP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
